Profile data is unavailable for this security.
About the company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
- Revenue in USD (TTM)2.86bn
- Net income in USD478.60m
- Incorporated1996
- Employees2.00k
- LocationNeurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 617-7600
- Fax+1 (858) 617-7602
- Websitehttps://www.neurocrine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.54bn | 283.00 | -- | 43.94 | -- | 37.54 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 8.02bn | 275.00 | 41.49 | 7.04 | 39.21 | 21.48 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.14bn | 683.00 | -- | 123.65 | -- | 16.28 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.34bn | 350.00 | 16.70 | 18.53 | 13.79 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.11bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.34 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.50bn | 3.04k | 22.44 | 1.90 | 19.07 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 12.46bn | 2.00k | 26.62 | 3.82 | 24.49 | 4.35 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.49bn | 9.00k | 350.88 | 1.85 | 17.69 | 2.72 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.50bn | 725.00 | -- | -- | -- | 40.99 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 16.50bn | 5.80k | -- | 1.91 | -- | 8.49 | -7.26 | -7.26 | 5.00 | 22.14 | 0.1468 | 5.34 | 7.17 | -- | -21.31 | 10.19 | -25.32 | 13.43 | 62.91 | 75.16 | -145.16 | 19.02 | 3.22 | -- | 0.0659 | -- | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 18.16bn | 32.00k | -- | 1.20 | -- | 1.29 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
Data as of Feb 13 2026. Currency figures normalised to Neurocrine Biosciences Inc's reporting currency: US Dollar USD
44.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 9.88m | 9.91% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.95m | 8.98% |
| Dodge & Coxas of 30 Sep 2025 | 5.56m | 5.57% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.35m | 4.36% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 4.03m | 4.04% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 2.78m | 2.79% |
| AQR Capital Management LLCas of 30 Sep 2025 | 2.77m | 2.78% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 2.42m | 2.43% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.02m | 2.03% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 1.76m | 1.77% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
